What is the current market price of Ribociclib and the most cost-effective price per box?

Ribociclib (Ribociclib), as a targeted drug for the treatment of breast cancer, is currently on the market as an original drug in the domestic market and has been included in the medical insurance system. The common specifications in the domestic market are 200mg*63 tablets, and each box sells for about 4,000 yuan. Due to the support of medical insurance, the financial burden of patients purchasing original drugs in China is relatively lightened, which makes purchasing Riboxil through domestic formal channels the first choice for many patients.

Compared with domestic prices, the price of Ribociclib in overseas markets is significantly higher. Taking the European version of the original drug as an example, the packaging specifications of 200mg*21 tablets, 42 tablets and 63 tablets are often sold in the market for more than 20,000 yuan per box. Such high prices not only greatly increase the cost of treatment for patients, but also limit the availability of medication for some patients. Therefore, although overseas versions of drugs are of reliable quality, price becomes a constraint.

It is worth noting that the price of the original research version of Ribocil in the Indian market is relatively affordable, with each box selling for about more than 2,000 yuan. However, the price will fluctuate due to factors such as exchange rates. In addition, generic versions of drugs have also appeared in overseas markets, such as 200mg*21 tablets produced by Lucius Pharmaceuticals in Laos, which may be sold for more than 1,000 yuan. This kind of generic drug is basically the same as the original drug in terms of ingredients and efficacy, and has obvious price advantages, providing patients with an affordable medication option.

Taken together, the domestic medical insurance coverage makes the price of purchasing the original drug of Riboxil more advantageous. At about more than 4,000 yuan per box, it is currently the most cost-effective choice for patients. For patients with limited budget or unable to purchase through medical insurance channels, generic versions of drugs in places such as India and Laos provide more economical alternatives. Patients should consider their own financial situation and medication needs when choosing, and choose a source of drugs that is both safe and cost-effective.

Reference materials:https://us.kisqali.com/